HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies
Author:
Frange Pierre12, Assoumou Lambert3, Descamps Diane45, Chéret Antoine26, Goujard Cécile67, Tran Laurent78, Gousset Marine1, Avettand-Fenoël Veronique12, Bocket Laurence9, Fafi-Kremer Samira1011, Guinard Jerome12, Morand-Joubert Laurence13, Nicot Florence14, Plantier Jean-Christophe15, Rogez Sylvie16, Wirden Marc17, Rouzioux Christine12, Meyer Laurence78, Chaix Marie-Laure18, Abel S., Abraham B., Allegre T., Antoniotti A., Armero R., Audhuy B., Aumaitre H., Beaucaire G., Beck-Wirth G., Berger J.L., Bernard L., Beuscart C., Bodard L., Bouchaud O., Boué F., Cabane J.-P., Cabie A., Champagne H., Cheneau C., Chennebault J.-M., Cheret A., Christian B., Compagnucci A., Daneluzzi V., Debab Y., Dellamonica P., Delfraissy J.-F., Devidas A., Diab G., Doll J., Drobacheff-Thebaut M.C., Durel A., Duvivier C., Esnault J.-L., Faba L., Froguel E., Garipuy D., Garrait V., Geffray L., Genet C., Genet P., Gerard L., Ghosn J., Girard J-.J., Girard P.-M., Godin-Collet C., Hochedez P., Hoen B., Houlbert D., Jacomet C., Jeantils V., Jidar K., Katlama C., Klement E., Lafeuillade A., Lascoux C., Launay V., Lepretre A., Levy Y., Makhloufi D., Malbec D., Martha B., May T., Merrien D., Miailhes P., Miodovski C., Molina J.-M., Morlat P., Mortier E., Neau D., Obadia M., Patey O., Pellegrin J.-L., Perronne V., Philibert P., Pialoux G., Pichancourt G., Piroth L., Poinsignon Y., Poizot-Martin I., Prazuck T., Prendki V., du Clary F. Preveteau, Quinsat D., Raffi F., Regnier A., Reynes J., Rosenthal E., Rouveix E., Salmon D., Salanville F., Schmitt J.-L., Simon-Coutellier A., Sotto A., Souala F., Stein A., Timsit F., de Truchis P., Uludag A., Vaillant O., Verdon R., Verlesch-Langlin A., Viard J.-P., Vittecoq D., Weiss L., Yéni P., Zucman D., Allavena C., Allegre T., Amri I., Autran B., Bacchus C., Blanc C., Bonne S., Bonnet B., Bouchez S., Charlier C., Consigny P.-H., Duvivier C., Fourn E., Guiroy F., Huleux T., Katlama C., Lascoux-Combe C., Leplatois A., Lyavanc T., Molina J.-M., Naqvi A., Nembot G., Quertainmont Y., Raffi F., Samri A., Schneider L., Seang S., Seksik B.C.P., Shoai-Tehrani M., Slama L., Valentin M.-A., Yazdanpanah Y., Alloui C., Amiel C., André P., André-Garnier E., Anies G., Barin F., Bellecave P., Bettinger D., Bouvier-Alias M., Brun-Vézinet F., Calmy A., Calvez V., Caveng W., Chaillon A., Chapalay S., Charpentier C., Costagliola D., Cottalorda J., Delamare C., Delaugerre C., Dina J., Santos G. Dos, Férré V., Flandre P., Fleury H., Fourati S., Gaille C., Giraudeau G., Guigon A., Haim-Boukobza S., Lagier E., Le Guillou-Guillemette H., Henquell C., Izopet J., Lambert-Niclot S., Leroux M., Maillard A., Malet I., Marcelin A.-G., Marque-Juillet S., Masquelier B., Mirand A., Morand P., Montes B., Mouna L., Noel C., Pallier C., Peytavin G., Pinson-Recordon P., Poveda J.D., Raymond S., Reigadas S., Roques A.-M., de Rougemont A., Roussel C., Schmitt M.-P., Schneider V., Schvoerer E., Signori-Schmuck A., Soulié C., Tamalet C., Tardy J.C., Trabaud M.-A., Vabret A., Vallet S., Yerly S.,
Affiliation:
1. 1 Laboratoire de Microbiologie, Assistance Publique—Hôpitaux de Paris (AP-HP), Hôpital Necker—Enfants Malades, Paris, France 2. 2 EA7327, Université Paris Descartes, Sorbonne Paris Cité, Paris, France 3. 3 Sorbonne Universités, UPMC Université Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France 4. 4 Laboratoire de Virologie, AP-HP, Hôpital Bichat–Claude Bernard, Paris, France 5. 5 INSERM UMR1137 IAME, Université Paris Diderot, F-75018 Paris, France 6. 6 Service de médecine interne, AP-HP, Hôpital Bicêtre, Le Kremlin Bicêtre, France 7. 7 INSERM CESP, U1018, Université Paris Sud, Faculté de Médecine Paris Sud, Le Kremlin Bicêtre, France 8. 8 Département d'Epidémiologie, AP-HP, Hôpital Bicêtre, Le Kremlin Bicêtre, France 9. 9 Laboratoire de Virologie, Centre hospitalo-universitaire de Lille, Lille, France 10. 10 Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France 11. 11 INSERM, U1109, LabEx TRANSPLANTEX Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France 12. 12 Laboratoire de Microbiologie, Centre hospitalier régional d'Orléans, Orléans, France 13. 13 Laboratoire de Virologie, AP-HP, Hôpital Saint Antoine, Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France 14. 14 Laboratoire de Virologie, Institut fédératif de biologie de Purpan, CHU de Toulouse, Hôpital Purpan, F-31300 Toulouse, France 15. 15 Laboratoire de Virologie et COREVIH Haute Normandie, Centre hospitalo-universitaire Charles Nicolle, Rouen, France 16. 16 Laboratoire de Virologie, Centre hospitalo-universitaire de Limoges, Limoges, France 17. 17 Laboratoire de Virologie, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France 18. 18 Laboratoire de Virologie, AP-HP, Hôpital Saint Louis, INSERM U941, Université Paris Diderot, Laboratoire associé au Centre national de Référence du VIH, Paris, France
Abstract
Abstract
Background
Our study describes the prevalence of transmitted drug resistance (TDR) among 1318 French patients diagnosed at the time of primary HIV-1 infection (PHI) in 2007–12.
Methods
HIV-1 resistance-associated mutations (RAMs) were characterized using both the 2009 WHO list of mutations and the French ANRS algorithm. A genotypic susceptibility score was estimated for each first-line recommended ART combination.
Results
Patients were mainly MSM (72.6%). Non-B variants were identified in 33.7% of patients. The proportion of TDR was estimated as 11.7% (95% CI 10.0–13.5). The prevalences of PI-, NRTI-, first-generation NNRTI and etravirine/rilpivirine-associated RAMs were 2.5%, 5.2%, 3.9% and 3.2%, respectively. Single, dual and triple class resistance was found in 9.6%, 1.0% and 1.1% of cases, respectively. Additionally, 5/331 strains isolated in 2010–12 had integrase inhibitor (II)-related RAMs (isolated E157Q mutation in all cases). TDR was more common among MSM than in other groups (12.9% versus 8.6%, P = 0.034), and in case of B versus non-B subtype infections (13.6% versus 7.9%, P = 0.002). The proportions of fully active combinations were ≥99.2%, ≥97.3% and ≥95.3% in cases of PI-, II- and NNRTI-based regimens, respectively. In 2010–12, the proportion of fully active efavirenz-based ART was lower in cases of subtype B versus non-B infection (P = 0.021).
Conclusions
Compared with our previous studies, the proportion of NRTI- and first-generation NNRTI-related TDR has continued to decline in French seroconverters. However, subtype B-infected MSM could drive the spread of resistant HIV strains. Finally, we suggest preferring PI- or II- to NNRTI-based combinations to treat PHI patients.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|